I use a broad range of mathematical tools ranging from statistical physics, ecology, pharmacology, and epidemiology to inform vaccination, treatments, and cures for infectious diseases like SARS-CoV-2 and HIV. You can find out more at https://www.fredhutch.org/en/research/divisions/vaccine-infectious-disease-division/faculty-labs/vidd-staff-scientists-physicians/reeves-daniel.html (FHCC), and www.dbrvs.org (personal). 

I am a statistical physicist by training, graduated from Virginia Tech in 2019. My burning desire to understand the complexity and interconnectedness of the human body sparked during my sister’s battle with cancer and only grew over time.  After three years of post-graduate work at the interface between modeling ecological systems with statistical physics, I joined the fantastic, diverse group of scientists at the Vaccine and Infectious Disease Division to understand and model the virus dynamics and its interaction with the immune system. Here at Schiffer’s group, I’m modeling gene drive technology in herpes viruses and the pharmacokinetic and pharmacodynamic modeling of combination therapy and simulating a clinical trial.

I have worked for several years in the Schiffer group developing compartmental and agent-based spatial models for various infectious diseases with a primary focus on HSV.  Additionally, I have worked with several other groups at Fred Hutchinson providing simulation expertise and other types of computing support. Prior to working at Fred Hutchinson, I was a senior software engineer with F5 Networks and Boeing as well as serving as a high school teacher with the Peace Corps in Kenya, East Africa. I have a degree in Electrical Engineering from Stanford and graduate degrees in Computer Science and Medical Engineering from UW.

I studied mathematics at Willamette University and applied mathematics at the University of Washington before joining the Schiffer group as a post-doctoral research fellow in spring 2022. I am excited about using mechanistic mathematical models to address open questions in biology and medicine. In my current work, I aim to understand the within-host dynamics and evolution of SARS-CoV-2 during infection in order to inform optimal treatment plans for immunocompromised patients and clinical trial design.